1型糖尿病中运动诱导的免疫调节:从机制到临床前景
本文综述运动对1型糖尿病免疫调节作用的证据,涵盖固有与适应性免疫变化、啮齿类及人β细胞临床前数据,以及观察性和干预性临床研究。总体而言,直接临床证据有限,但临床前与早期人体数据支持运动具有生物学上合理的免疫调节作用,或可作为低风险联合治疗。
要点
- 运动可减少胰岛炎症、限制免疫细胞浸润并保护β细胞免受细胞因子损伤。
- 运动诱导抗炎运动因子如meteorin样蛋白和irisin。
- 较高体力活动与更长部分缓解期、减缓胰岛自身免疫进展相关。
核心结论
- 尽管直接临床证据有限,汇聚的临床前与早期人体数据支持运动在1型糖尿病中具有生物学上合理的免疫调节作用。
研究设计与样本
- 本文为综述,批判性审视运动诱导免疫调节在1型糖尿病中的当前证据。
主要发现
- 运动改变固有与适应性免疫,包括免疫细胞表型、细胞因子和趋化因子谱及肌肉来源介质。
- 啮齿类模型和人β细胞系统显示运动减少胰岛炎症、限制免疫细胞浸润、保护β细胞免受细胞因子诱导损伤。
- 运动诱导抗炎运动因子如meteorin样蛋白和irisin。
- 观察性和干预性研究将较高体力活动水平与更长部分缓解、减缓胰岛自身免疫进展及抗炎免疫特征相关联。
临床怎么用
- 结构化运动可能作为低风险联合治疗,尤其在诊断早期或与新兴免疫疗法联合时。
局限性
- 直接临床证据仍然有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Type 1 diabetes is a chronic autoimmune disease driven by immune-mediated destruction of pancreatic β-cells. While technological advances in insulin delivery and glucose monitoring have improved glycemic management, they do not address the underlying autoimmune process. Identifying low-risk adjunct strategies that can modulate immune dysfunction therefore remains a clinical and translational priority. Physical exercise is a cornerstone of type 1 diabetes management for its metabolic benefits, yet its potential role as an immunomodulatory intervention has received comparatively little attention. This review critically examines current evidence on exercise-induced immune modulation in type 1 diabetes. We first summarize the effects of exercise on innate and adaptive immunity, including changes in immune-cell phenotypes, cytokine and chemokine profiles, and muscle-derived mediators. We then synthesize preclinical data from rodent models and human β-cell systems showing that exercise reduces islet inflammation, limits immune-cell infiltration, protects β-cells from cytokine-induced injury, and induces anti-inflammatory exerkines such as meteorin-like protein and irisin. Finally, we review available clinical evidence in individuals with type 1 diabetes, including observational and interventional studies linking higher levels of physical activity to longer partial remission, reduced progression of islet autoimmunity, and anti-inflammatory immune signatures. Overall, although direct clinical evidence remains limited, converging preclinical and early human data support a biologically plausible immunoregulatory role for exercise in type 1 diabetes. We discuss therapeutic perspectives where structured exercise may act as a low-risk cotherapy, particularly early after diagnosis or in combination with emerging immunotherapies, and highlight key priorities for future clinical trials.
引用
- Cook DA, Perna-Barrull D, Murillo M, et al. Exercise-Induced Immune Modulation in Type 1 Diabetes: From Mechanisms to Clinical Perspectives. Diabetes Care. 2026. PMID: 42284195. doi:10.2337/dci26-0044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。